Pharmala Biotech Holdings Inc
Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada.
Pharmala Biotech Holdings Inc (MDXXF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of November 2025: -0.049x
Based on the latest financial reports, Pharmala Biotech Holdings Inc (MDXXF) has a cash flow conversion efficiency ratio of -0.049x as of November 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-116.22K) by net assets ($2.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pharmala Biotech Holdings Inc - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Pharmala Biotech Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Pharmala Biotech Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pharmala Biotech Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aurea SA
PA:AURE
|
0.119x |
|
Daewoo SBI SPAC 1
KQ:215480
|
-0.057x |
|
Gaxos.ai Inc
NASDAQ:GXAI
|
-0.080x |
|
Wow Factor PCL
BK:W
|
-0.002x |
|
Sparc Technologies Ltd
AU:SPN
|
-0.290x |
|
Advancecon Holdings Bhd
KLSE:5281
|
0.102x |
|
Mendus AB (publ)
ST:IMMU
|
-0.139x |
|
YD More Investments Ltd
TA:MRIN
|
0.208x |
Annual Cash Flow Conversion Efficiency for Pharmala Biotech Holdings Inc (2021–2025)
The table below shows the annual cash flow conversion efficiency of Pharmala Biotech Holdings Inc from 2021 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-08-31 | $2.46 Million | $-1.04 Million | -0.425x | -161.78% |
| 2024-08-31 | $1.98 Million | $-321.36K | -0.162x | +33.93% |
| 2023-08-31 | $1.38 Million | $-339.66K | -0.246x | +25.16% |
| 2022-08-31 | $1.91 Million | $-625.37K | -0.328x | -401.86% |
| 2021-08-31 | $2.66 Million | $-173.57K | -0.065x | -- |